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Abstract
Uncoupling protein 2 (UCP2) is a mitochondrial membrane protein that plays a role in uncou-
pling electron transport from adenosine triphosphate (ATP) formation. Polymorphisms of
the UCP2 gene in humans affect protein expression and function and have been linked to
survival into old age. Since UCP2 is expressed in several brain regions, we investigated in
this study whether UCP2 polymorphisms might 1) affect occurrence of neurodegenerative
or mental health disorders and 2) affect measures of brain structure and function. We used
structural magnetic resonance imaging (MRI), diffusion-weighted MRI and resting-state
functional MRI in the neuroimaging sub-study of the Whitehall II cohort. Data from 536 indi-
viduals aged 60 to 83 years were analyzed. No association of UCP2 polymorphisms with
the occurrence of neurodegenerative disorders or grey and white matter structure or rest-
ing-state functional connectivity was observed. However, there was a significant effect on
occurrence of mood disorders in men with the minor alleles of -866G>A (rs659366) and
Ala55Val (rs660339)) being associated with increasing odds of lifetime occurrence of mood
disorders in a dose dependent manner. This result was not accompanied by effects of
UCP2 polymorphisms on brain structure and function, which might either indicate that the
sample investigated here was too small and underpowered to find any significant effects, or
that potential effects of UCP2 polymorphisms on the brain are too subtle to be picked up by
any of the neuroimaging measures used.
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Introduction
Uncoupling protein (UCP) 2 is a proton carrier found in the inner mitochondrial membrane. It
is responsible for uncoupling electron transport through the electron transfer chain from the
active pumping of protons across the inner mitochondrial membrane, thus uncoupling electron
transport from adenosine triphosphate (ATP) formation [1]. UCP2 is abundantly expressed in
brain tissue and in non-human primates it can be found in areas, such as the hypothalamic
nuclei, pituitary gland, brainstem (incl. raphe nucleus and locus coeruleus), ventral tegmental
area and substantia nigra [2]. There are few investigations of UCP2 expression in the human
brain but expression has been shown in the cortex and basal ganglia with increased expression
in the periphery of ischemic stroke lesions [3]. It affects neuronal function in multiple ways, e.g.
as a regulator of production of reactive oxygen species (ROS) [4]. Thus UCP2 provides a plausi-
ble link between mitochondrial (dys-)function, ROS production, ageing and neurodegeneration
[5]. For example, UCP2 overexpression in mice protects neurons in the substantia nigra of a
Parkinson’s disease model [6]. UCP2 also appears to play a role in neuronal plasticity and
regeneration [7], and human UCP2 expression extends the lifespan of flies and mice [8].
There are several polymorphisms of the UCP2 gene in humans. The most frequently inves-
tigated polymorphisms are the -866G>A promoter polymorphism, which affects UCP2
mRNA expression, and the Ala55Val polymorphism in the exon of the gene leading to a substi-
tution of amino acids, which affects the degree of uncoupling and thus protein function [4].
Some studies have shown links between these polymorphisms and risk of obesity, insulin resis-
tance and diabetes [9], although there are many conflicting reports on these effects [10]. A
study that investigated the effects of UCP gene variants on longevity found that UCP2 poly-
morphisms affect survival into old age [11].
Due to the potential link between UCP2 gene variants, ROS production and longevity, we
investigated in this study, whether UCP2 polymorphisms affect the risk of developing neurode-
generative diseases and whether they account for any variance in brain structure or function.
We examined data from the Whitehall II imaging sub-study. Whitehall II is an ongoing epi-
demiological study that has followed-up an initial cohort of 10,000 British civil servants since
1985, with the aim of advancing knowledge of the causal chain through which social circum-
stances influence health [12]. Over the past 30 years a wealth of social, behavioural and biologi-
cal data have been acquired, which makes Whitehall II a unique study of ageing. Within the
Whitehall II imaging sub-study brain magnetic resonance imaging (MRI) scans of 800 partici-
pants randomly selected from the original Whitehall II study of 10,308 British civil servants
were acquired [13]. In the study presented here, data from 563 individuals aged 60 to 83 years
that have been scanned prior to January 2016 were analyzed.
We investigated effects of UCP2 polymorphisms on risk of neurodegenerative disease
(defined as having a clinical diagnosis of Parkinson’s disease, Alzheimer’s disease, mild cogni-
tive impairment (MCI), stroke, transient ischemic attack or multiple sclerosis) and the risk of
having a lifetime diagnosis of mental health disorder (defined as current or past episodes of
mood disorders or anxiety disorders) in this sample. To determine effects of UCP2 polymor-
phisms on brain structure and function, we investigated grey and white matter structure, as
well as functional brain connectivity at rest, using structural, diffusion and functional MRI.
Material and methods
Participants
In order to make the Whitehall II neuroimaging sub-sample as representative as possible of
the cohort at baseline, a random sample of 800 Whitehall II Phase 11 participants willing and
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able to give informed consent were invited to attend the imaging sub-study at the Oxford Cen-
tre for Functional MRI of the Brain (FMRIB). To achieve a sufficient number of participants
with depression, we enriched the sample by 30 participants with depressive symptoms based
on previous Whitehall II clinical examinations. We excluded participants with contraindica-
tions to MRI scanning (including but not limited to a history of claustrophobia, certain metal-
lic implants and metallic injury to the eye), or who were unable to travel to Oxford without
assistance. Data from 563 individuals aged 60 to 83 years that have been scanned prior to Janu-
ary 2016 were included in the analyses.
Ethical approval for the Whitehall II study was obtained from the University College Lon-
don Medical School committee on the ethics of human research and all participants provided
written informed consent. Ethical approval for neuroimaging data acquisition was granted
generically for the “Protocol for non-invasive magnetic resonance investigations in healthy
volunteers” (MSD/IDREC/2010/P17.2) by the University of Oxford Central University/ Medi-
cal Science Division Interdisciplinary Research Ethics Committee (CUREC/ MSD-IDREC),
who also approved the specific protocol: “Predicting MRI abnormalities with longitudinal data
of the Whitehall II sub-study” (MSD-IDREC-C1-2011-71, PI: KPE). The Health Research
Authority NRES Committee South Central—Oxford C approved the study: “Biological mecha-
nisms and risk factors in late onset depression” (REC Reference: 10/H0606/71, PI: CLA) that
allowed us to examine participants with a past history of depressive symptoms.
The study follows the Medical Research Council (MRC) Policy on data sharing, i.e. images
and other data will be available for analysis by other groups after completion of the study, as is
the case with the Whitehall II study (see http://www.ucl.ac.uk/whitehallII/data-sharing).
Clinical and cognitive assessment
Each participant recruited for the Whitehall II imaging sub-study underwent a detailed clinical
and cognitive assessment lasting up to two hours. The clinical assessment consisted of a (A)
self-administered questionnaire, a (B) semi-structured clinical interview and (C) cognitive
assessment. For this study only a subset of the data was used, which is described here in more
detail. For an overview of all assessments, please see [13].
- General Health Questionnaire-30 (GHQ-30 [14]): The GHQ-30 is a 30-item self-adminis-
tered screening questionnaire for the detection of psychiatric illness in non-psychiatric clin-
ical and community settings.
- Montreal Cognitive Assessment (MoCA [15]): The MoCA is a 30-point cognitive screening
test assessing multiple cognitive domains: visuo-spatial abilities, short-term memory recall,
executive function, attention, orientation and working memory, language and orientation
to time and space.
- Centre for Epidemiological Studies Depression Scale (CES-D [16]): The CES-D is short self-
report scale that measures major depressive symptomatology in the general population.
- Test of Premorbid Functioning (TOPF [17]): The TOPF consists of a list of seventy written
words, which must be read aloud and is marked according to pronunciation. The TOPF is
used to estimate an individual’s level of intellectual functioning before the onset of injury or
illness. Premorbid IQ can be calculated from the raw score, adjusted for sex and years of
education.
- Structured Clinical Interview for DSM-IV-TR Axis I Disorders [18]: The SCID-I is a semi-
structured interview for diagnosing current and past DSM-IV Axis I disorders and is
administered by a trained graduate psychologist or psychiatrist.
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Genotyping
DNA was extracted from whole blood samples (via magnetic bead technology; Medical Solu-
tions, Nottingham, UK) and normalized to a concentration of 50 ng/μl. Participants were
genotyped for two polymorphisms of the UCP2 gene, -866G>A (rs659366) and Ala55Val
(rs660339) using SNPLex (Applied Biosciences, Inc., Warrington, United Kingdom) by Medi-
cal Solutions Plc (Nottingham, United Kingdom)[19].
Neuroimaging data acquisition
A detailed description of the image acquisition protocols and pre-processing steps for neuro-
imaging data can be found in [13]. In brief, scanning was carried out at FMRIB using a 3 T
Siemens Magnetom Verio (Erlangen, Germany) Scanner with a 32-channel receive head coil.
The neuroimaging protocol comprised both structural and functional sequences and lasted
approximately 50 minutes. The MRI sequences that were analyzed for this study included
high-resolution T1-weighted MRI (multi-echo MPRAGE [20], TR = 2530 ms, TE = 1.79/3.65/
5.51/7.37 ms, flip angle = 7˚, field of view = 256 mm, voxel dimension = 1 mm isotropic,
acquisition time = 6 min 12 s), diffusion MRI (dMRI) (TR = 8900 ms, TE = 91.2 ms, field
of view = 192 mm, voxel dimension = 2 mm isotropic, B-value = 1500 s/mm2, gradients
applied = 60 isotropically distributed diffusion-weighted directions with b-value = 1500 s/
mm2, 5 non-diffusion weighted images, b-value 0s/mm2, with one b0 volume acquired in the
reversed phase encoded direction, acquisition time = 9 min 56 s) and resting-state functional
MRI (rsfMRI) (multiband echo-planar imaging, TR = 1300 ms, TE = 40 ms, flip angle = 66˚,
field of view = 212 mm, voxel dimension = 2 mm isotropic, acquisition time = 10 min 10 s).
For the rsfMRI scan subjects were instructed to lie in dimmed light with their eyes open, blink
normally, but not to fall asleep.
Neuroimaging data pre-processing
For neuroimaging data pre-processing we used standard FMRIB Software Library (FSL)
tools v5.0 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) [21]. A detailed description of the data pre-
processing steps can be found in [13]. The pre-processing pipeline for T1-weighted images
included: re-orientating images to the standard (MNI) template, bias field correction, regis-
tration to the MNI template using both linear (FLIRT) and non-linear (FNIRT) registration
tools and brain extraction. Brain tissues were segmented using FMRIB’s Automated Seg-
mentation Tool (FAST) that allows extracting measures of total grey matter (GM), white
matter (WM) and cerebrospinal fluid (CSF) [22]. Brain tissues and sub-cortical regions
were visually inspected to ensure an accurate segmentation, and manually edited where
necessary.
The pre-processing pipeline for diffusion MRI data used a recently developed approach
that simultaneously considers and corrects for susceptibility-induced distortions, eddy-cur-
rents and head motion, which is based on methods developed and applied to the Human
Connectome Project (HCP) diffusion MRI data [23]. Fractional anisotropy (FA), mean diffu-
sivity (MD), axial (DA) and radial diffusivity (DA) maps were generated using DTIFit, part of
FMRIB’s Diffusion Toolbox, that fits a diffusion tensor model at each voxel [24].
Resting-state fMRI data pre-processing consisted of motion correction, brain extraction,
high-pass temporal filtering with a cut-off of 100 s, and field-map correction and was carried
out using FSL Multivariate Exploratory Linear Optimized Decomposition into Independent
Components (MELODIC) [25]. To identify and regress out the “signal” of artefactual compo-
nents reflecting non-neuronal fluctuations, we used single-subject independent component
analysis (ICA) followed by an automatic component classification with FMRIB’s ICA-based
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X-noiseifier (FIX) [26, 27]. The pre-processed and “cleaned” functional data was registered to
the individual’s structural scan and standard space images using FNIRT, then optimized using
boundary-based-registration approach [28], and finally spatially smoothed using an isotropic
Gaussian kernel of 6 mm full width at half maximum (FWHM).
Neuroimaging data analysis
For data analysis we used standard FSL tools v5.0.
To study grey matter (GM) morphology, the T1-weighted structural imaging data were ana-
lysed using a voxel-based morphometry (VBM) approach. Whole-brain analysis was carried
out with FSL-VBM [29], using default settings.
FMRIB’s Integrated Registration and Segmentation Tool (FIRST [30]), an automated
model-based segmentation/registration tool, was applied to extract volumes of sub-cortical
GM structures. Volumes were normalized to total intracranial volume and imported into SPSS
for further statistical analyses.
White matter integrity (FA, MD, DA and DR) was analysed using FMRIB’s Diffusion
Toolbox and tract-based spatial statistics (TBSS), a voxelwise approach for analysis of FA (and
MD, DA, DR) data [31].
Functional connectivity was analysed using the FSL dual regression method [32]. Connec-
tivity of 8 standard resting-state networks defined by a group ICA using MELODIC was ana-
lysed: the default-mode network, executive control network, two visual networks, the auditory
and sensory-motor networks and left and right fronto-parietal networks [25].
For all image-based analyses (VBM, TBSS, dual regression) voxelwise general linear
modelling (GLM) was applied using permutation nonparametric testing (5000 permuta-
tions) and P<0.05 correcting for multiple comparisons across space using threshold-free
cluster enhancement (TFCE) [33]. Three UCP2 haplotype groups were compared in this
model. Due to the significant effects of UCP2 polymorphisms on lifetime risk of mood disor-
ders in men in this sample, we carried out two different analyses of the neuroimaging data.
In the first analysis, all participants were included irrespective of sex and lifetime occurrence
of mood disorder. One-way ANOVAs were performed to determine UCP2 haplotype group
effects on imaging measures and post-hoc tests were performed to compare means between
the three groups. In the second analysis, we only included male participants and investigated
main effects of UCP2 haplotype and lifetime occurrence of mood disorders and their interac-
tion on brain structure and function using a two-way ANOVA. Age was used as a covariate
of no interest in all analyses.
Non-image based statistics
We used SPSS software version 23 (SPSS Inc., Chicago, USA) for non-image-based statistical
analyses and to compare volumes of subcortical structures. χ2 tests were used to compare alle-
lic distributions and determine Hardy-Weinberg equilibrium as well as to compare categorical
variables between the three UCP2 haplotype groups. Gene-dose effects were analyzed using
Mantel-Haenszel linear-by-linear association χ2 tests. Linkage disequilibrium between the two
UCP2 polymorphisms was determined using the online tool CubeX [34] (http://www.oege.
org/software/cubex/). One-way ANOVAs and post-hoc tests with Bonferroni correction were
used to compare continuous sociodemographic variables and subcortical volumes between
haplotype groups. An alpha of P<0.05 was considered significant but adjusted for multiple
comparison if necessary using Bonferroni correction (alpha was divided by the number of
comparisons).
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Results
Frequencies of UCP2 polymorphisms
Genotype data were available for 436 of the 563 individuals included in this analysis. Overall,
the observed UCP genotype frequencies were in Hardy-Weinberg equilibrium (p = 0.62 for
-866G>A and p = 0.57 for Ala55Val, Table 1) with values that are similar to those found in the
1000 genomes project (p = 0.59 for -866G>A and p = 0.58 for Ala55Val). The two polymor-
phisms showed strong linkage disequilibrium with D’ = 0.99 and r2 = 0.80.
Effect of UCP2 polymorphisms on occurrence of neurodegenerative or
mental health disorders
UCP2 polymorphisms did not significantly affect occurrence of neurodegenerative diseases in
this sample. Occurrence of neurodegenerative disease was defined as having a clinical diagno-
sis of Alzheimer’s disease, Parkinsons’s disease, stroke, transient ischaemic attack, multiple
sclerosis or mild cognitive impairment (based on clinical diagnosis or a MoCA score< 26).
There was a non-significant trend to an overrepresentation of the minor alleles in participants
with current or past diagnosis of mental health disorders, according to the SCID (χ2(2,
n = 436) = 5.27, P<0.1 for -866A and χ2(2, n = 436) = 5.18, P<0.1 for 55Val) (Table 1). To
study possible gender effects, we investigated male and female populations separately. The
overrepresentation of both minor alleles was only significant in male participants (χ2(2,436) =
8.67, P<0.05 for -866A and χ2(2, n = 436) = 9.94, P<0.01 for 55Val) but not in female partici-
pants (Table 1).
For the G(-866)A polymorphism, there was a higher risk of having current or past diagnosis
of mental health disorder for men who carried one (OR = 1.63, 95% CI = 0.96–2.76) or two
minor alleles (OR = 2.77, 95% CI = 1.38–5.57) compared with homozygotes for the major allele
(Table 2). For the Ala55Val polymorphism there was a higher risk of having current or past diag-
nosis of mental health disorder for men who carried one (OR = 2.05, 95% CI = 1.15–3.64) or two
minor alleles (OR = 2.91, 95% CI = 1.44–5.87) compared with homozygotes for the major allele
(Table 2). The gene-dose effect was significant for both polymorphisms (χ2(1, n = 359) = 8.56,
P<0.01 for -866A and χ2(1, n = 359) = 9.64, P<0.01 for 55Val).
Table 1. Comparisons of allelic distributions across the whole sample and between participants with and without mental health disorders.
Whole sample Male Female
Total MHD No MHD P Total MHD No MHD P Total MHD No MHD P
n 436 137 299 359 101 258 77 36 41
G(−866)A (rs659366) 0.07 0.013 0.30
G/G 0.38 0.33 0.40 0.38 0.28 0.41 0.39 0.47 0.32
G/A 0.48 0.48 0.48 0.48 0.51 0.47 0.48 0.39 0.56
A/A 0.14 0.19 0.11 0.14 0.21 0.11 0.13 0.14 0.12
MAF (−866)A 0.38 0.43 0.36 0.38 0.47 0.35 0.37 0.33 0.40
Ala55Val (rs660339) 0.08 0.007 0.49
C/C 0.32 0.26 0.35 0.31 0.20 0.36 0.35 0.42 0.29
C/T 0.51 0.53 0.50 0.52 0.56 0.50 0.48 0.42 0.54
T/T 0.17 0.22 0.15 0.17 0.24 0.15 0.17 0.17 0.17
MAF 55Val 0.43 0.48 0.40 0.43 0.52 0.40 0.41 0.38 0.44
MAF: minor allele frequency, MHD: mental health disorder, P values are based on χ2 tests, significant P values are shown in bold.
https://doi.org/10.1371/journal.pone.0181392.t001
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We then investigated whether specific diagnoses were overrepresented in those who carried
one or two minor alleles of the two polymorphisms. 97 out of 101 participants who reported
current or past episodes of mental health disorders suffered from mood disorders (defined as
bipolar disorder, dysthymic disorder, recurrent or single episode major depressive disorder
and unspecified mood disorders, which includes minor depression). The numbers for each of
the disorders were insufficient to conduct any further statistical analyses.
We sought to replicate this effect in a larger Whitehall II sample of 5025 participants who
took part in phase 9 (data collected from 2007–2009) and were genotyped for UCP2. However,
there was no SCID data available for these participants. Therefore, participants were classified
as having a current or past episode of mood disorder according to a definition used in previous
Whitehall II studies [35]: a total score of 5 or more on the GHQ, a total score of 16 or more on
the CES-D and the use of antidepressant medication in any of the previous Whitehall II phases.
Using this metric, we were not able to replicate the significant effect of UCP2 polymorphisms
on occurrence of mood disorders in the larger sample.
Neuroimaging data analysis of haplotype groups
Due to the strong linkage disequilibrium between the two UCP2 polymorphisms, participants
were grouped according to three different haplotype groups for all analyses of neuroimaging
data: homozygotes for the major alleles (called haplotype group 1 (HT1)), homozygotes for
minor alleles (HT3), and heterozygotes (HT2). Out of the 436 participants included in this
analysis, 317 participants fell into one of these three groups and had complete neuroimaging
datasets available. There were 112 participants in HT group 1, 155 in HT2 and 50 in HT3.
These groups did not show any differences in socio-demographic variables (age, years of edu-
cation, MOCA score, IQ or body-mass index (BMI), Table 3). Although the sex distribution in
this sample is representative of the overall Whitehall II sample in that around 80% of all partic-
ipants are male, the three haplotype groups did not significantly differ in sex distributions.
Due to the significant effects of UCP2 polymorphisms on lifetime risk of mood disorders in
men in this sample, we carried out two different analyses of the neuroimaging data. In the first
analysis, all participants were included irrespective of sex and lifetime occurrence of mood dis-
order. There were no significant differences between UCP2 haplotype groups for any of the
neuroimaging measures investigated here. All non-thresholded statistical images for these
analyses can be found on NeuroVault [36]: http://neurovault.org/collections/IAGLVJEJ/. In
the second analysis, we only included male participants and investigated main effects of UCP2
haplotype group and lifetime occurrence of mood disorders and their interaction. Again, there
Table 2. Comparisons of risk and odds between the genotypes in men.
Total (n) MHD (n) No MHD (n) RE RR OE OR
G(−866)A (rs659366)
G/G 135 28 107 0.21 1 0.26 1
G/A 174 52 122 0.30 1.44 0.43 1.63 (0.96–2.76)
A/A 50 21 29 0.42 2.03 0.72 2.77 (1.38–5.57)
Ala55Val (rs660339)
C/C 112 20 92 0.18 1 0.22 1
C/T 185 57 128 0.31 1.73 0.45 2.05 (1.15–3.64)
T/T 62 24 38 0.39 2.17 0.63 2.91 (1.44–5.87)
MHD: mental health disorder, RE: risk estimates, RR: risk ratios (compared with homozygotes for major allele), OE: odds estimates, OR: odds ratios
compared with homozygotes for major allele (with 95% confidence interval in brackets).
https://doi.org/10.1371/journal.pone.0181392.t002
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was no significant main effect of UCP2 haplotype group and no significant interaction between
UCP2 haplotype group and lifetime occurrence of mood disorders for any of the neuroimaging
measures.
Discussion
We set out to investigate possible effects of UCP2 polymorphisms on the risk of developing
neurodegenerative disease but did not find significant effects in this sample. There are two
possible explanations for this. On the one hand it is possible that the sample in this study was
too small to detect significant effects and a larger study with more statistical power would be
needed to rule this out. On the other hand it is possible that UCP2 polymorphisms do not play
a role in the development of neurodegenerative disorders. This interpretation is backed up by
the fact that UCP2 polymorphisms have not been reported in genome-wide association studies
(GWAS) that investigated genetic factors underlying risk of Alzheimer’s disease (e.g. [37]) or
Parkinson’s disease (e.g. [38]). However, we observed a significant effect of UCP2 polymor-
phisms on the occurrence of mood disorders in men in this sample. This effect was significant
for both UCP2 polymorphisms and showed a gene-dose effect in that those who carry two
minor alleles had nearly threefold increased odds of lifetime occurrence of mood disorders
and those with one minor allele a twofold elevated odds compared with those who are homo-
zygote for the major alleles. While this is an intriguing finding, we could not replicate the effect
in the larger Whitehall II sample. However, there are no data available for lifetime occurrence
of mental health disorders for the larger sample, and we were only able to use proxy markers
that will give an indication whether participants had a mood disorder when they were tested
during the last 30 years. While UCP2 polymorphisms have not been reported in GWAS for
major depressive disorders (e.g. [39]) there are several reasons why it would still be worth fol-
lowing up on. First, patient data for GWAS often comes from those who have severe episodes
of depression and are hospitalized. However, only very few participants included in this
Whitehall II sub-study suffered from severe depression. In most cases they reported episodes
of minor depression. Second, there are two important differences with regards to the age and
sex distribution of the sample investigated here and those included in GWAS. The average age
of participants in this study is around 70 years, which is different from many other samples
that have a much lower average age, in most cases between 40 and 50 years (e.g. [40]). In addi-
tion, the sex distribution is different since around 80% of Whitehall II participants are men,
whereas other samples have a much higher proportion of female patients from 50–80% (e.g.
[40]). Therefore, UCP2 polymorphisms might be genetic risk factors that affect lifetime occur-
rence of less severe mood disorders particularly in men. This would be a further indication of
Table 3. Comparisons of socio-demographic variables between the haplotype groups included in the neuroimaging analysis.
HT1 (GG/CC) HT2 (GA/CT) HT3 (AA/TT) P Value
n 112 155 50
Age 69.7 (5.4) 69.3 (5.4) 69.9 (5.5) 0.70
Sex (n and % women) 23 (20.5%) 25 (16.1%) 9 (18%) 0.65
Total years of education 15.7 (3.3) 15.6 (3.6) 15.4 (3.4) 0.88
MOCA score 27.4 (2.1) 27.4 (2.1) 27.3 (2.2) 0.93
IQ 118.9 (9.5) 118.7 (10.0) 117.9 (9.6) 0.82
BMI 25.6 (4.4) 26.6 (4.2) 26.8 (3.7) 0.1
Values denote mean (±Standard Deviation) or number of subjects, P-values refer to one-way ANOVAs (parametric data) and chi-square tests (categorical
data).
https://doi.org/10.1371/journal.pone.0181392.t003
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a link between mitochondrial (dys-)function and mood disorders [41]. However, it is a result
that will need to be replicated independently.
To our knowledge this is the first study to investigate effects of UCP2 polymorphisms on
human brain structure and function using neuroimaging data. We did not find any significant
effects of UCP2 haplotype group on grey or white matter structure or resting-state functional
connectivity. One interpretation is that UCP2 polymorphisms do not affect brain structure or
function. However, it is also possible that the sample investigated here was too small to find
any significant effects, or that effects of UCP2 polymorphisms on the brain are too subtle to be
picked up by any of the neuroimaging measures here. Again, a larger study sample would be
required to clarify these questions.
Conclusion
In conclusion, we show in a sub-sample of the Whitehall II study that UCP2 polymorphisms
do not significantly affect grey or white matter structure or resting-state functional connectiv-
ity. An interesting effect of UCP2 polymorphisms on lifetime occurrence of mood disorders
requires independent replication.
Acknowledgments
We would like to thank all participants and the Whitehall staff at UCL, who so helpfully collab-
orate with us. We are grateful to all FMRIB staff, in particular radiographers Jon Campbell,
Michael Sanders, Caroline Young and David Parker, IT staff David Flitney, Christopher Galla-
gher, Duncan Mortimer and Matthew Webster, FMRIB administrative staff Sue Field and
Marilyn Goulding, Barbora Krausova and especially KPE’s PA Amanda Pipkin, for help with
coordinating the appointments. We would like to thank Martin Turner and his colleagues for
advising on incidental findings and taking over clinical responsibility for such participants.
We are grateful for provision of the multiband pulse sequence and reconstruction algorithms
to the Center for Magnetic Resonance Research, University of Minnesota, USA. We are grate-
ful to Siemens Healthcare for the provision of the DTI and MEMPR sequences. The DTI
sequence was a Works-in-Progress package for advanced EPI diffusion imaging, developed by
Thorsten Feiweier, Siemens AG, Healthcare Sector, Erlangen, Germany. The Multi-Echo
MPRAGE sequence is a Works-in-Progress package, developed by Siemens in collaboration
with the Athinoula A. Martinos, Center for Biomedical Imaging, Massachusetts General Hos-
pital. Work on this study was mainly funded by the “Lifelong Health and Wellbeing” Pro-
gramme Grant: “Predicting MRI abnormalities with longitudinal data of the Whitehall II
Substudy” (UK Medical Research Council: G1001354). Collection of blood and buccal mucosal
samples for a characterization of immune function and associated measures is supported by
the UK Medical Research Council grant K013351 and the ESRC professional fellowship
scheme to MK. ASM receives research support from the US National Institutes of Health
(R01AG013196, R01AG034454). NF, SS and AM are funded by the HDH Wills 1965 Charita-
ble Trust (Nr: 1117747). VH, CS and CEM are supported by the National Institute for Health
Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals
NHS Trust, Oxford Health NHS Foundation Trust and University of Oxford (The views
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health).
Author Contributions
Conceptualization: VH CEM KPE.
UCP2 haplotype does not affect human brain structure and function
PLOS ONE | https://doi.org/10.1371/journal.pone.0181392 August 3, 2017 9 / 12
Data curation: EZ AM.
Formal analysis: VH.
Funding acquisition: ASM MK KPE.
Investigation: VH EZ SS CS AT NF AM CLA.
Project administration: EZ CEM KPE.
Resources: ASM MK.
Supervision: CEM KPE.
Validation: VH KPE.
Writing – original draft: VH.
Writing – review & editing: EZ SS CS AT NF AM CLA ASM MK CEM KPE.
References
1. Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell
Biol. 2005; 6(3):248–61. PMID: 15738989.
2. Diano S, Urbanski HF, Horvath B, Bechmann I, Kagiya A, Nemeth G, et al. Mitochondrial uncoupling
protein 2 (UCP2) in the nonhuman primate brain and pituitary. Endocrinology. 2000; 141(11):4226–38.
Epub 2000/11/23. https://doi.org/10.1210/endo.141.11.7740 PMID: 11089557.
3. Nakase T, Yoshida Y, Nagata K. Amplified expression of uncoupling proteins in human brain ischemic
lesions. Neuropathology: official journal of the Japanese Society of Neuropathology. 2007; 27(5):442–
7. PMID: 18018477.
4. Donadelli M, Dando I, Fiorini C, Palmieri M. UCP2, a mitochondrial protein regulated at multiple levels.
Cell Mol Life Sci. 2014; 71(7):1171–90. https://doi.org/10.1007/s00018-013-1407-0 PMID: 23807210.
5. Cardoso S, Correia S, Carvalho C, Candeias E, Placido AI, Duarte AI, et al. Perspectives on mitochon-
drial uncoupling proteins-mediated neuroprotection. J Bioenerg Biomembr. 2015; 47(1–2):119–31.
Epub 2014/09/15. https://doi.org/10.1007/s10863-014-9580-x PMID: 25217852.
6. Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Yang L, Beal MF, et al. Uncoupling protein-2 is criti-
cal for nigral dopamine cell survival in a mouse model of Parkinson’s disease. J Neurosci. 2005; 25
(1):184–91. https://doi.org/10.1523/JNEUROSCI.4269-04.2005 PMID: 15634780.
7. Dietrich MO, Andrews ZB, Horvath TL. Exercise-induced synaptogenesis in the hippocampus is depen-
dent on UCP2-regulated mitochondrial adaptation. J Neurosci. 2008; 28(42):10766–71. https://doi.org/
10.1523/JNEUROSCI.2744-08.2008 PMID: 18923051;
8. Dietrich MO, Horvath TL. The role of mitochondrial uncoupling proteins in lifespan. Pflugers Arch. 2010;
459(2):269–75. https://doi.org/10.1007/s00424-009-0729-0 PMID: 19760284;
9. Andersen G, Dalgaard LT, Justesen JM, Anthonsen S, Nielsen T, Thorner LW, et al. The frequent
UCP2 -866G>A polymorphism protects against insulin resistance and is associated with obesity: a
study of obesity and related metabolic traits among 17 636 Danes. Int J Obes (Lond). 2013; 37(2):175–
81. Epub 2012/02/22. https://doi.org/10.1038/ijo.2012.22 PMID: 22349573.
10. Qian L, Xu K, Xu X, Gu R, Liu X, Shan S, et al. UCP2 -866G/A, Ala55Val and UCP3 -55C/T polymor-
phisms in association with obesity susceptibility—a meta-analysis study. PLoS One. 2013; 8(4):
e58939. https://doi.org/10.1371/journal.pone.0058939 PMID: 23560041;
11. Rose G, Crocco P, De Rango F, Montesanto A, Passarino G. Further support to the uncoupling-to-sur-
vive theory: the genetic variation of human UCP genes is associated with longevity. PLoS One. 2011; 6
(12):e29650. https://doi.org/10.1371/journal.pone.0029650 PMID: 22216339;
12. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. Int J Epidemiol. 2005; 34(2):251–6. Epub
2004/12/04. https://doi.org/10.1093/ije/dyh372 PMID: 15576467.
13. Filippini N, Zsoldos E, Haapakoski R, Sexton CE, Mahmood A, Allan CL, et al. Study protocol: The
Whitehall II imaging sub-study. BMC Psychiatry. 2014; 14:159. Epub 2014/06/03. https://doi.org/10.
1186/1471-244X-14-159 PMID: 24885374;
14. Goldberg DW P. A user’s guide to the general health questionnaire. London: GL Assessment Limited.
2006.
UCP2 haplotype does not affect human brain structure and function
PLOS ONE | https://doi.org/10.1371/journal.pone.0181392 August 3, 2017 10 / 12
15. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cog-
nitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;
53(4):695–9. Epub 2005/04/09. https://doi.org/10.1111/j.1532-5415.2005.53221.x PMID: 15817019.
16. Radloff L. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population.
Applied Psychological Measurement. 1977; 1:385–401.
17. Wechsler D. Test of Premorbid Functioning. UK Version (TOPF UK). Bloomington, MN: Pearson Inc.;
2011.
18. First M, Gibbon M, Spitzer R, Williams J. User’s Guide for the Structured Clinical Interview for DSM-IV-
TR Axis I Disorders—Research Version—(SCID-I for DSM-IV-TR), November 2002 Revision: New
York: Biometric Research Department, New York State Psychiatric Intitute; 2002.
19. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept, design and
implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association
studies. PLoS One. 2008; 3(10):e3583. https://doi.org/10.1371/journal.pone.0003583 PMID:
18974833;
20. van der Kouwe AJ, Benner T, Salat DH, Fischl B. Brain morphometry with multiecho MPRAGE. Neuro-
image. 2008; 40(2):559–69. https://doi.org/10.1016/j.neuroimage.2007.12.025 PMID: 18242102;
21. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances
in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004; 23
Suppl 1:S208–19. https://doi.org/10.1016/j.neuroimage.2004.07.051 PMID: 15501092.
22. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field
model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001; 20(1):45–57. Epub
2001/04/11. https://doi.org/10.1109/42.906424 PMID: 11293691.
23. Sotiropoulos SN, Jbabdi S, Xu J, Andersson JL, Moeller S, Auerbach EJ, et al. Advances in diffusion
MRI acquisition and processing in the Human Connectome Project. Neuroimage. 2013; 80:125–43.
https://doi.org/10.1016/j.neuroimage.2013.05.057 PMID: 23702418;
24. Behrens T, Woolrich M, Jenkinson M, Johansen-Berg H, Nunes R, Clare S, et al. Characterization and
propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med. 2003; 50(5):1077–88.
https://doi.org/10.1002/mrm.10609 PMID: 14587019
25. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using
independent component analysis. Philos Trans R Soc Lond B Biol Sci. 2005; 360(1457):1001–13. Epub
2005/08/10. https://doi.org/10.1098/rstb.2005.1634 PMID: 16087444;
26. Salimi-Khorshidi G, Douaud G, Beckmann CF, Glasser MF, Griffanti L, Smith SM. Automatic denoising
of functional MRI data: combining independent component analysis and hierarchical fusion of classifi-
ers. Neuroimage. 2014; 90:449–68. https://doi.org/10.1016/j.neuroimage.2013.11.046 PMID:
24389422;
27. Griffanti L, Salimi-Khorshidi G, Beckmann CF, Auerbach EJ, Douaud G, Sexton CE, et al. ICA-based
artefact removal and accelerated fMRI acquisition for improved resting state network imaging. Neuro-
image. 2014; 95:232–47. https://doi.org/10.1016/j.neuroimage.2014.03.034 PMID: 24657355;
28. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration.
NeuroImage. 2009; 48(1):63–72. Epub 2009/07/04. https://doi.org/10.1016/j.neuroimage.2009.06.060
PMID: 19573611;
29. Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, et al. Anatomically related
grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007; 130(Pt 9):2375–
86. Epub 2007/08/19. https://doi.org/10.1093/brain/awm184 PMID: 17698497.
30. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for
subcortical brain segmentation. Neuroimage. 2011; 56(3):907–22. https://doi.org/10.1016/j.
neuroimage.2011.02.046 PMID: 21352927;
31. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based
spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006; 31(4):1487–
505. Epub 2006/04/21. https://doi.org/10.1016/j.neuroimage.2006.02.024 PMID: 16624579.
32. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of
brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA. 2009; 106
(17):7209–14. https://doi.org/10.1073/pnas.0811879106 PMID: 19357304.
33. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing,
threshold dependence and localisation in cluster inference. NeuroImage. 2009; 44(1):83–98. Epub
2008/05/27. https://doi.org/10.1016/j.neuroimage.2008.03.061 PMID: 18501637.
34. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequen-
cies: implications for linkage disequilibrium analyses and a web tool ’CubeX’. BMC bioinformatics.
2007; 8:428. https://doi.org/10.1186/1471-2105-8-428 PMID: 17980034;
UCP2 haplotype does not affect human brain structure and function
PLOS ONE | https://doi.org/10.1371/journal.pone.0181392 August 3, 2017 11 / 12
35. Kivimaki M, Shipley MJ, Allan CL, Sexton CE, Jokela M, Virtanen M, et al. Vascular risk status as a pre-
dictor of later-life depressive symptoms: a cohort study. Biol Psychiatry. 2012; 72(4):324–30. https://
doi.org/10.1016/j.biopsych.2012.02.005 PMID: 22425413;
36. Gorgolewski KJ, Varoquaux G, Rivera G, Schwarz Y, Ghosh SS, Maumet C, et al. NeuroVault.org: a
web-based repository for collecting and sharing unthresholded statistical maps of the human brain.
Frontiers in neuroinformatics. 2015; 9:8. https://doi.org/10.3389/fninf.2015.00008 PMID: 25914639;
37. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of
74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013; 45
(12):1452–8. https://doi.org/10.1038/ng.2802 PMID: 24162737;
38. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of
genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014; 46
(9):989–93. https://doi.org/10.1038/ng.3043 PMID: 25064009;
39. Major Depressive Disorder Working Group of the Psychiatric GC, Ripke S, Wray NR, Lewis CM, Hamil-
ton SP, Weissman MM, et al. A mega-analysis of genome-wide association studies for major depres-
sive disorder. Mol Psychiatry. 2013; 18(4):497–511. https://doi.org/10.1038/mp.2012.21 PMID:
22472876;
40. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, et al. Genome-wide
association study of major depressive disorder: new results, meta-analysis, and lessons learned. Mol
Psychiatry. 2012; 17(1):36–48. https://doi.org/10.1038/mp.2010.109 PMID: 21042317;
41. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, et al. Impaired mitochondrial function in
psychiatric disorders. Nat Rev Neurosci. 2012; 13(5):293–307. https://doi.org/10.1038/nrn3229 PMID:
22510887.
UCP2 haplotype does not affect human brain structure and function
PLOS ONE | https://doi.org/10.1371/journal.pone.0181392 August 3, 2017 12 / 12
